1. Calcium channel blockers can inhibit the transmembrane calcium ion influx of myocardial and vascular smooth muscle without changing the blood calcium concentration, and have high vascular selectivity; 2. Dilate coronary vascular smooth muscle, increase the exercise tolerance of patients with chronic stable angina pectoris, and reduce the frequency of angina attacks; 3. Reduce the body's peripheral vascular resistance, lower blood pressure, and reduce the systolic and diastolic blood pressure of patients with mild and moderate hypertension, but do not change the circadian rhythm of blood pressure; 4. Increase cardiac ejection fraction and cardiac output, and the left ventricular end-diastolic pressure does not change much; 5. Can temporarily increase urinary sodium excretion; 6. Block slow calcium channels without affecting fast sodium channels.

This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.

Participates in the formation of bones and the reconstruction of bone tissue after fracture, muscle contraction, nerve transmission, coagulation process and reduces the permeability of capillaries, etc.